Triprolidine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Allergic conditions

Adult: For the temporary relief of symptoms (e.g. runny nose, sneezing, eye, nose or throat itching) associated with allergic rhinitis or other upper respiratory allergies: 2.5 mg 4-6 hourly. Max: 10 mg in 24 hours.
Child: For the temporary relief of symptoms (e.g. runny nose, sneezing, eye, nose or throat itching) associated with allergic rhinitis or other upper respiratory allergies: 6-<12 years 1.25 mg 4-6 hourly (Max: 5 mg in 24 hours); ≥12 years Same as adult dose. Dosing recommendations may vary among individual products (refer to specific product guidelines).

Administration

May be taken with or without food.

Special Precautions

Patient with breathing problems (e.g. chronic bronchitis, emphysema), glaucoma, pyloroduodenal obstruction, bladder-neck obstruction, symptomatic prostatic hypertrophy; history of bronchial asthma, increased IOP, hyperthyroidism, CV disease (e.g. hypertension). Children and elderly. Pregnancy and lactation.

Adverse Reactions

Significant: CNS depression; excitability (particularly in children).
Eye disorders: Blurred vision.
Gastrointestinal disorders: Dry mouth, nausea, vomiting, heartburn.

Patient Counseling Information

This drug may cause drowsiness, if affected, do not drive or operate machinery.

Drug Interactions

Increased sedation with CNS depressants (e.g. sedatives, tranquilisers). May enhance the anticholinergic effects with MAOIs and TCAs.

Food Interaction

May increase drowsiness with alcohol.

Action

Description:
Mechanism of Action: Triprolidine, an alkylamine derivative, is an H₁-receptor antagonist with antimuscarinic and mild sedating effects. It provides dose-related inhibition of histamine-induced wheal and flare reactions which results in the prevention and suppression of the signs and symptoms of allergic rhinitis and other upper respiratory allergies.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 1.7 ± 0.5 hours.
Distribution: Enters breast milk.
Metabolism: Metabolised extensively in the liver.
Excretion: Via urine (approx 1% as unchanged drug). Elimination half-life: 2.1 ± 0.8 hours.

Chemical Structure

Storage

Store between 15-30°C.

MIMS Class

Antihistamines & Antiallergics

ATC Classification

R06AX07 - triprolidine ; Belongs to the class of other antihistamines for systemic use.

References

Anon. Triprolidine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 09/03/2023.

Anon. Triprolidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/03/2023.

Buckingham R (ed). Triprolidine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/03/2023.

Childrens PediaClear PD Liquid (GM Pharmaceuticals, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/03/2023.

Flonase Nighttime Allergy Relief Tablet (GlaxoSmithKline Consumer Healthcare Holdings [US] LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/03/2023.

Histex PD Drops (Allegis Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/03/2023.

Histex Syrup (Allegis Pharmaceuticals, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/03/2023.

Miclara LQ Liquid (Key Therapeutics). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 09/03/2023.

Disclaimer: This information is independently developed by MIMS based on Triprolidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com